Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2013

01.06.2013 | Thoracic Oncology

Postchemoradiation Resected Locally Advanced Esophageal and Gastroesophageal Junction Carcinoma: Long-Term Outcome With or Without Intraoperative Radiotherapy

verfasst von: Felipe A. Calvo, MD, PhD, Claudio V. Sole, MD, Rosángela Obregón, MD, PhD, Marina Gómez-Espí, MD, Miguel A. Lozano, MD, Luis Gonzalez-Bayon, MD, PhD, Jose Luis García-Sabrido, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

To report feasibility, tolerance, anatomical topography of locoregional recurrence (LRR), and long-term outcome for esophageal and esophagogastric (EG) cancer patients treated with preoperative chemoradiation (CRT) and surgery with or without a radiation boost of intraoperative electron beam radiotherapy (IOERT).

Methods

From January 1995 to December 2010, 53 patients with primary esophageal (n = 26; 44 %) or EG carcinoma (n = 30; 56 %), and disease confined to locoregional area [clinical stage: IIb (n = 30; 57 %), IIIa (n = 14; 26 %), IIIb (n = 6; 11 %), IIIc (n = 3; 6 %)], were treated with preoperative CRT, curative (R0) resection with an extended (two-field) lymph node dissection in all cases. Thirty-seven patients also received a preanastomotic reconstruction IOERT boost (applicator diameter size 6–9 cm, dose 10–15 Gy, beam energy 6–15 MeV) over the tumor bed in the mediastinum and upper abdominal lymph node area.

Results

With a median follow-up time of 27.9 months (range, 0.2–148), LRR rate was 15 % (n = 8). Five-year overall survival (OS) and disease-free survival was 48 and 36 %, respectively. Univariate log-rank analyses showed that receiving IOERT was associated with lower risk of LRR (p = 0.004). On multivariate analysis, only the IOERT group retained significance in relation to LRR (odds ratio, 0.08; 95 % confidence interval, 0.01–0.48; p = 0.01). Postoperative mortality and perioperative complications were 11 % (n = 6) and 30 % (n = 16).

Conclusions

Local control is high in the radiation-boosted area, but OS remains modest, given the high risk of distant metastases. Intensified locoregional treatment needs to be tested in the context of more efficient concurrent, neo-, and adjuvant systemic therapy.
Literatur
1.
Zurück zum Zitat Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.PubMedCrossRef Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062–7.PubMedCrossRef
2.
Zurück zum Zitat Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment of carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.PubMedCrossRef Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment of carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.PubMedCrossRef
3.
Zurück zum Zitat Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48:411–20.PubMedCrossRef Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48:411–20.PubMedCrossRef
4.
Zurück zum Zitat Collard JM, Otte JB, Reynaert MS, Michel LA, Malaise JF, Lengele BG, et al. Extensive lymph node clearance for cancer of the esophagus or cardia: merits in reference to 5-year absolute survival. Hepatogastroenterology. 1995;42:619–27.PubMed Collard JM, Otte JB, Reynaert MS, Michel LA, Malaise JF, Lengele BG, et al. Extensive lymph node clearance for cancer of the esophagus or cardia: merits in reference to 5-year absolute survival. Hepatogastroenterology. 1995;42:619–27.PubMed
5.
Zurück zum Zitat Nishimaki T, Tanaka O, Suzuki T, Aizawa K, Hatakeyama K, Muto T, et al. Clinical implications of cervical lymph node metastasis patterns in thoracic esophageal cancer. Ann Surg. 1994;20:775–81.CrossRef Nishimaki T, Tanaka O, Suzuki T, Aizawa K, Hatakeyama K, Muto T, et al. Clinical implications of cervical lymph node metastasis patterns in thoracic esophageal cancer. Ann Surg. 1994;20:775–81.CrossRef
6.
Zurück zum Zitat Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654–62.PubMedCrossRef Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222:654–62.PubMedCrossRef
7.
Zurück zum Zitat Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg. 1997;113:540–4.PubMedCrossRef Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg. 1997;113:540–4.PubMedCrossRef
8.
Zurück zum Zitat Mariette C, Piessen G, Triboulet J-P. Therapeutic strategies in esophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545–53.PubMedCrossRef Mariette C, Piessen G, Triboulet J-P. Therapeutic strategies in esophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545–53.PubMedCrossRef
9.
Zurück zum Zitat Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRef Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRef
10.
Zurück zum Zitat Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev. 2005;4:CD001799. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev. 2005;4:CD001799.
11.
Zurück zum Zitat Zieren HU, Muller JM, Jacobi CA, Pichlmaier H, Muller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995;19:444–9.PubMedCrossRef Zieren HU, Muller JM, Jacobi CA, Pichlmaier H, Muller RP, Staar S. Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg. 1995;19:444–9.PubMedCrossRef
12.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RH, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2001;12:681–92.CrossRef Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RH, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2001;12:681–92.CrossRef
13.
Zurück zum Zitat Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRef Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.PubMedCrossRef
14.
Zurück zum Zitat Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRef Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–7.PubMedCrossRef
15.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.PubMedCrossRef
16.
Zurück zum Zitat Fletcher G. Clinical dose-response curves of human malignant epithelial tumours Br J Radiol. 1973;46:1–12. Fletcher G. Clinical dose-response curves of human malignant epithelial tumours Br J Radiol. 1973;46:1–12.
17.
Zurück zum Zitat Gunderson LL, Willet CG, Calvo FA, Harrison LB. Intraoperative irradiation techniques and results. In: Okunnief P, Sundararaman S, Metcalfe S, Chen Y, editors. Biology of large dose per fraction irradiation vol. 2. 2nd edn. Current Clinical Oncology. Totowa: Humana Press; 2011. p. 27–50. Gunderson LL, Willet CG, Calvo FA, Harrison LB. Intraoperative irradiation techniques and results. In: Okunnief P, Sundararaman S, Metcalfe S, Chen Y, editors. Biology of large dose per fraction irradiation vol. 2. 2nd edn. Current Clinical Oncology. Totowa: Humana Press; 2011. p. 27–50.
18.
Zurück zum Zitat Hosokawa M, Shirato H, Ohara M, et al. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer. 1999;86:6–13.PubMedCrossRef Hosokawa M, Shirato H, Ohara M, et al. Intraoperative radiation therapy to the upper mediastinum and nerve-sparing three-field lymphadenectomy followed by external beam radiotherapy for patients with thoracic esophageal carcinoma. Cancer. 1999;86:6–13.PubMedCrossRef
19.
Zurück zum Zitat Murakami M, Kuroda Y, Nakajima T, et al. Intraoperative radiotherapy for the abdominal lymphatic system in patients with esophageal carcinoma. Dis Esophagus. 1999;12:270–5.PubMedCrossRef Murakami M, Kuroda Y, Nakajima T, et al. Intraoperative radiotherapy for the abdominal lymphatic system in patients with esophageal carcinoma. Dis Esophagus. 1999;12:270–5.PubMedCrossRef
20.
Zurück zum Zitat Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, Deschamps C. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus. 2006;19:487–95.PubMedCrossRef Miller RC, Haddock MG, Gunderson LL, Donohue JH, Trastek VF, Alberts SR, Deschamps C. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus. 2006;19:487–95.PubMedCrossRef
21.
Zurück zum Zitat Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;21:1662–9.CrossRef Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;21:1662–9.CrossRef
22.
Zurück zum Zitat Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2001;71:1803–8.PubMedCrossRef Visbal AL, Allen MS, Miller DL, Deschamps C, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2001;71:1803–8.PubMedCrossRef
23.
Zurück zum Zitat Orringer MB, Marshall B, Chang AC, Lee J, MS, Pickens A, Lau CL. Two thousand transhiatal esophagectomies. Changing trends, lessons learned. Ann Surg. 2007;246:363–74. Orringer MB, Marshall B, Chang AC, Lee J, MS, Pickens A, Lau CL. Two thousand transhiatal esophagectomies. Changing trends, lessons learned. Ann Surg. 2007;246:363–74.
24.
Zurück zum Zitat Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1993;106:850–8.PubMed Hagen JA, Peters JH, DeMeester TR. Superiority of extended en bloc esophagogastrectomy for carcinoma of the lower esophagus and cardia. J Thorac Cardiovasc Surg. 1993;106:850–8.PubMed
25.
Zurück zum Zitat Pascau J, Santos Miranda JA, Calvo FA, Bouché A, Morillo V, González-San Segundo C, Ferrer C, López Tarjuelo J, Desco M. An innovative tool for intraoperative electron beam radiotherapy simulation and planning: description and initial evaluation by radiation oncologists. Int J Radiat Oncol Biol Phys. 2012;83:287–95. Pascau J, Santos Miranda JA, Calvo FA, Bouché A, Morillo V, González-San Segundo C, Ferrer C, López Tarjuelo J, Desco M. An innovative tool for intraoperative electron beam radiotherapy simulation and planning: description and initial evaluation by radiation oncologists. Int J Radiat Oncol Biol Phys. 2012;83:287–95.
26.
Zurück zum Zitat Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.PubMedCrossRef Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.PubMedCrossRef
27.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;20:851–6.CrossRef Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Königsrainer A, Budach W, Wilke H. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;20:851–6.CrossRef
28.
Zurück zum Zitat Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.PubMedCrossRef Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310–7.PubMedCrossRef
29.
Zurück zum Zitat Azinovic I, Calvo FA, Puebla F, Aristu J, Martínez-Monge R. Long-term normal tissue effects of intraoperative electron radiation therapy (IOERT): late sequelae, tumor recurrence, and second malignancies. Int J Radiat Oncol Biol Phys. 2001;49:597–604.PubMedCrossRef Azinovic I, Calvo FA, Puebla F, Aristu J, Martínez-Monge R. Long-term normal tissue effects of intraoperative electron radiation therapy (IOERT): late sequelae, tumor recurrence, and second malignancies. Int J Radiat Oncol Biol Phys. 2001;49:597–604.PubMedCrossRef
30.
Zurück zum Zitat Birkmeyer JD, Siewers AE, Finlayson E, et al. Hospital volume and surgical mortality in the United States. N Eng J Med. 2002;346:1128–37.CrossRef Birkmeyer JD, Siewers AE, Finlayson E, et al. Hospital volume and surgical mortality in the United States. N Eng J Med. 2002;346:1128–37.CrossRef
31.
Zurück zum Zitat Nguyen NT, Follette DM, Lemoine PH, Roberts PF, Goodnight JE Jr. Minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg. 2001;72:593–6.PubMedCrossRef Nguyen NT, Follette DM, Lemoine PH, Roberts PF, Goodnight JE Jr. Minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg. 2001;72:593–6.PubMedCrossRef
32.
Zurück zum Zitat Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:1078–85. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:1078–85.
33.
Zurück zum Zitat Song YP, Ma JB, Hu LK, Zhou W, Chen EC, Zhang W. Phase I/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma. Technol Cancer Res Treat. 2011;10:25–30.PubMed Song YP, Ma JB, Hu LK, Zhou W, Chen EC, Zhang W. Phase I/II study of hypofractioned radiation with three-dimensional conformal radiotherapy for clinical T3-4N0-1M0 stage esophageal carcinoma. Technol Cancer Res Treat. 2011;10:25–30.PubMed
Metadaten
Titel
Postchemoradiation Resected Locally Advanced Esophageal and Gastroesophageal Junction Carcinoma: Long-Term Outcome With or Without Intraoperative Radiotherapy
verfasst von
Felipe A. Calvo, MD, PhD
Claudio V. Sole, MD
Rosángela Obregón, MD, PhD
Marina Gómez-Espí, MD
Miguel A. Lozano, MD
Luis Gonzalez-Bayon, MD, PhD
Jose Luis García-Sabrido, MD, PhD
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2810-8

Weitere Artikel der Ausgabe 6/2013

Annals of Surgical Oncology 6/2013 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.